Arbutus Biopharma Corp


Prices are adjusted according to historical splits.

Arbutus Biopharma Corp Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$476.33 million
Book Value:
Revenue TTM:
$39.02 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Arbutus Biopharma Corp had its IPO on 2015-08-03 under the ticker symbol ABUS.

The company operates in the Healthcare sector and Biotechnology industry. Arbutus Biopharma Corp has a staff strength of 0 employees.

Stock update

Shares of Arbutus Biopharma Corp opened at $2.95 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $2.88 - $3.01, and closed at $3.

This is a +1.35% increase from the previous day's closing price.

A total volume of 550,703 shares were traded at the close of the day’s session.

In the last one week, shares of Arbutus Biopharma Corp have increased by +2.04%.

Arbutus Biopharma Corp's Key Ratios

Arbutus Biopharma Corp has a market cap of $476.33 million, indicating a price to book ratio of 2.8064 and a price to sales ratio of 11.6763.

In the last 12-months Arbutus Biopharma Corp’s revenue was $39.02 million with a gross profit of $-45389000 and an EBITDA of $-61796000. The EBITDA ratio measures Arbutus Biopharma Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Arbutus Biopharma Corp’s operating margin was -162.03% while its return on assets stood at -19.76% with a return of equity of -45.35%.

In Q4, Arbutus Biopharma Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 94.8%.

Arbutus Biopharma Corp’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Arbutus Biopharma Corp’s profitability.

Arbutus Biopharma Corp stock is trading at a EV to sales ratio of 7.6703 and a EV to EBITDA ratio of -4.5333. Its price to sales ratio in the trailing 12-months stood at 11.6763.

Arbutus Biopharma Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$195.42 million
Total Liabilities
$32.86 million
Operating Cash Flow
$12.68 million
Capital Expenditure
Dividend Payout Ratio

Arbutus Biopharma Corp ended 2023 with $195.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $195.42 million while shareholder equity stood at $136.85 million.

Arbutus Biopharma Corp ended 2023 with $0 in deferred long-term liabilities, $32.86 million in other current liabilities, 1318737000.00 in common stock, $-1203803000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $30.78 million and cash and short-term investments were $146.91 million. The company’s total short-term debt was $372,000 while long-term debt stood at $0.

Arbutus Biopharma Corp’s total current assets stands at $151.14 million while long-term investments were $37.36 million and short-term investments were $116.14 million. Its net receivables were $4.23 million compared to accounts payable of $16.03 million and inventory worth $0.

In 2023, Arbutus Biopharma Corp's operating cash flow was $12.68 million while its capital expenditure stood at $59000.

Comparatively, Arbutus Biopharma Corp paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Arbutus Biopharma Corp stock is currently trading at $3 per share. It touched a 52-week high of $3.22 and a 52-week low of $3.22. Analysts tracking the stock have a 12-month average target price of $5.4.

Its 50-day moving average was $2.85 and 200-day moving average was $2.52 The short ratio stood at 6.54 indicating a short percent outstanding of 0%.

Around 2565.7% of the company’s stock are held by insiders while 3331.4% are held by institutions.

Frequently Asked Questions About Arbutus Biopharma Corp

The stock symbol (also called stock or share ticker) of Arbutus Biopharma Corp is ABUS

The IPO of Arbutus Biopharma Corp took place on 2015-08-03

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.


701 Veterans Circle, Warminster, PA, United States, 18974